New four-drug cocktail shows promise for hard-to-treat myeloma

NCT ID NCT07150091

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults with relapsed or refractory multiple myeloma who have already tried at least three other treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how well the combination shrinks tumors. Because multiple myeloma is a chronic cancer that often requires ongoing therapy, this approach aims to control the disease rather than cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Salvador, Estado de Bahia, 41253-190, Brazil
GSK Investigational Site

São Paulo, 04537-080, Brazil
GSK Investigational Site

Halifax, Nova Scotia, B3H 1V7, Canada
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Hamburg, 22083, Germany
GSK Investigational Site

Athens, 11528, Greece
GSK Investigational Site

Mexico City, 01330, Mexico
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 06351, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Ulsan, 44033, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.